Spotlight on Neurology

Credits: 0.50 CME / CNE
Clinical Trial Update: Therapeutic Strategies to Delay Disease Progression
Richard Isaacson, MD
AcademicCME

Clinical Trial Update: Therapeutic Strategies to Delay Disease Progression

Start

Accredited By

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credits
0.5 CNE Contact Hours
Released: December 7, 2017
Expires: April 5, 2019
30 Minutes to complete

Target Audience

Neurologists, internists, nurse practitioners, and other healthcare professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

  1. Analyze clinical trial data of emerging therapeutics to delay progression in the treatment of AD
  2. Implement shared decision making with the multidisciplinary team and patients/caregivers to develop individualized treatment plans and referral to clinical studies to advance treatment and improve the quality of life for patients with AD

Activity Description

In this module of a Four-Part Expert Interview Series, Dr. Marc E. Agronin, along with Dr. Richard S. Isaacson, course chair, will evaluate available therapeutic options for Alzheimer’s disease (AD) patient. The faculty will highlight the evolution of failed and existing therapies in AD, and their impact on current clinical care, emphasizing strategies for delaying disease progression in the modern day. Emerging therapies for the treatment and management of Alzheimer’s disease will also be assessed. Through completing this educational activity, learners will be better acquainted with emerging and emerged clinical trial data as it relates to AD care.

Statement of Educational Need

Health care team members need to be up-to-date on the most current strategies to delay disease progression in Alzheimer’s patients.

Agenda

Clinical Trial Update: Therapeutic Strategies to Delay Disease Progression

Faculty

Program Chair:
Richard S. Isaacson, MD

Associate Professor of Neurology
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York


Program Faculty:
Marc E. Agronin, MD

Vice President, Behavioral Health and Clinical Research
Miami Jewish Health
Affiliate Associate Professor of Psychiatry and Neurology
University of Miami Miller School of Medicine
Miami, Florida


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.


Faculty
Relationship Identified With:
Richard S. Isaacson, MD
Consultant/Advisor: Eli Lilly and Company; Neurotrack; 23 and Me
Marc E. Agronin, MD
Consultant/Advisor: Eli Lilly and Company
Speaker's Bureau: Allergan

Non-faculty

Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski, Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

Designation of Credit

AcademicCME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 0.5 CNE contact hours.

Instructions for Receiving Credit

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

Statement of Commercial Support

This activity has been supported by an independent educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Neurology Presentations

0.50 CME
Vindico
Managing Off Episodes in Patients With Parkinson’s Disease: Unmet Needs and Emerging Options

Managing Off Episodes in Patients With Parkinson’s Disease: Unmet Needs and Emerging Options

Start

Activity Chair

Mark F. Lew, MD, FAAN
Professor of Neurology
Director, Division of Movement Disorders
Vice-Chair, Department of Neurology
VanDerMeulen Chair in PD Research
Keck/USC School of Medicine
Los Angeles, CA

Disclosure: Consulting Fee: Adamas, AbbVie, Acadia, Cynapsus, Lundbeck, Neurocrine, Prexton, Revance, Teva, UCB, US WorldMeds
Speakers Bureau: Acadia, Adamas, Lundbeck, Neurocrine, Teva, UCB
Contracted Research: Acorda, Biotie, Enterin, Michael J. Fox Foundation,NeuroDerm, Parkinson's Study Group, Pharm2B

Faculty

Rajesh Pahwa, MD
Laverne & Joyce Rider Professor of Neurology
Chief, Parkinson & Movement Disorders Division
Director, Parkinson Foundation Center of Excellence
University of Kansas Medical Center
Kansas City, KS

Disclosure: Consulting Fee: Abbott Medical Optics, AbbVie, Acorda, Adamas, Sunovion, US WorldMeds
Speakers Bureau: AbbVie, Acorda, Sunovion
Contracted Research: Abbott Medical Optics, AbbVie, Acorda, Adamas, Bristol-Myers Squibb, Boston Scientific, Cala Health, Cavion, Cynapsus, Intec, Jazz, Kyowa, Lilly, Pfizer, Prexton, Roche, Sunovion, US WorldMeds

Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff

Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accredited By

This continuing medical education activity is provided by Vindico Medical Education.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credits
Released: August 30, 2018
Expires: August 30, 2019
0.5 hour to complete

Activity Description

Parkinson's disease is a progressive, chronic, neurodegenerative disorder that affects more than 10 million people worldwide. It is canonically regarded as a hypokinetic motor condition, with bradykinesia, resting tremor, and rigidity as its classic features. However, neuropsychiatric and other nonmotor symptoms can have a greater impact on patients’ quality of life. In early disease, the motor symptoms of many patients can be controlled with the use of levodopa. However, many patients gradually experience “off episodes” in which symptoms re-emerge, often in a severe and long-lasting form. This wearing-off effect of treatment can further reduce quality of life, but treatment options are limited. This CME activity will feature a panel discussion with 2 expert clinicians, who will assess recent therapeutic updates in the treatment of patients with Parkinson’s disease and the latest strategies to manage these off episodes.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the prevalence and burden of off episodes associated with Parkinson's disease
  • Identify patients with Parkinson's disease who are experiencing off episodes and adjust the care plan accordingly
  • Assess the latest clinical advances regarding available and emerging options for the management of off episodes in patients with Parkinson's disease

Target Audience

The intended audience for the activity is neurologists and other health care professionals involved in the treatment of patients with Parkinson's disease.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credits™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME
The France Foundation
Spinal Muscular Atrophy Expert Discussion Conference Series — Transformative Treatment for SMA

Spinal Muscular Atrophy Expert Discussion Conference Series — Transformative Treatment for SMA

Start

Conference Series: Part 2 of 3

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: August 21, 2018
Expires: August 20, 2019
30 minutes to complete

Accredited By

Target Audience

Neurologists, pediatric neurologists, neuromuscular specialists, pediatricians, genetic counselors, and other clinicians who see patients with spinal muscular atrophy

Learning Objectives

  • Explore the potential implications of gene therapy for SMA
  • Summarize key clinical trial data on available/emerging treatments for SMA

Activity Description

As new therapies emerge for spinal muscular atrophy (SMA) that include gene replacement and gene modifying therapies, clinicians need to consider the expectations for these treatments. Experts, Dr. Eugenio Mercuri, Dr. Richard Finkel, and Dr. Gyula Acsadi, recently discussed these emerging therapies and their implications on the clinical disease state at an international meeting. This activity is a recording of their roundtable discussion with informative slides broken into 3 parts. The first part discusses diagnosis, genetics, and the role of SMN in SMA. Part 2 explains the results of emerging clinical trial data. The final activity is a practical discussion about the implications of these new therapies for this lethal disease. Discussion topics include the durability of new and emerging treatments and changes to the standards of care for patients with SMA. This education is an engaging update on SMA from the leading experts in the field.

Statement of Educational Need

Many clinicians have questions regarding the genetics of spinal muscular atrophy. In addition, carrier screening is not routinely done, despite ACOG recommendations. Routine newborn testing is currently being considered in many states and internationally. Identification of the neuromotor deficits associated with SMA (and other conditions) is often inaccurate or delayed. As new therapies emerge that include gene replacement and gene modifying therapies, clinicians need to consider the expectations of these treatments. Gene replacement therapy is still a mystery to most clinicians. New therapies prompt a reevaluation of current standards of SMA care.

Agenda

  • Gene splicing modifiers
  • Gene replacement therapy MOA
  • Clinical trial results

Faculty

Eugenio Mercuri, MD, PhD (Chair)
Professor of Pediatric Neurology
Catholic University of the Sacred Heart
Rome, Italy

Dr. Eugenio Mercuri is a consultant for AveXis, Biogen, F. Hoffmann-La Roche, and IONIS. He is a principal investigator for Biogen/IONIS and F. Hoffmann-La Roche studies.


Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida, United States

Dr. Richard Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Novartis, and Roche. He receives clinical trial support from AveXis, Biogen, Catabasis, Cytokinetics, Ionis, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.


Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Hartford, Connecticut, United States

Dr. Gyula Acsadi serves as a consultant for AveXis, Biogen, and Serepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Serepta.


Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest

Activity Staff Disclosure

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME information.
  • Complete the CME activity
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis, Inc.

Disclaimer Statement

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME
The France Foundation
Spinal Muscular Atrophy Expert Discussion Conference Series — Questions About SMA Treatment

Spinal Muscular Atrophy Expert Discussion Conference Series — Questions About SMA Treatment

Start

Conference Series: Part 3 of 3

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: August 21, 2018
Expires: August 20, 2019
30 minutes to complete

Accredited By

Target Audience

Neurologists, pediatric neurologists, neuromuscular specialists, pediatricians, genetic counselors, and other clinicians who see patients with spinal muscular atrophy

Learning Objectives

  • Explain the genetic aspects of SMA, including its recessive nature, carriers, and recommendations for genetic screening
  • Explore the potential implications of gene therapy for SMA
  • Summarize key clinical trial data on available/ emerging treatments for SMA

Activity Description

As new therapies emerge for spinal muscular atrophy (SMA) that include gene replacement and gene modifying therapies, clinicians need to consider the expectations for these treatments. Experts, Dr. Eugenio Mercuri, Dr. Richard Finkel, and Dr. Gyula Acsadi, recently discussed these emerging therapies and their implications on the clinical disease state at an international meeting. This activity is a recording of their roundtable discussion with informative slides broken into 3 parts. The first part discusses diagnosis, genetics, and the role of SMN in SMA. Part 2 explains the results of emerging clinical trial data. The final activity is a practical discussion about the implications of these new therapies for this lethal disease. Discussion topics include the durability of new and emerging treatments and changes to the standards of care for patients with SMA. This education is an engaging update on SMA from the leading experts in the field.

Statement of Educational Need

Many clinicians have questions regarding the genetics of spinal muscular atrophy. In addition, carrier screening is not routinely done, despite ACOG recommendations. Routine newborn testing is currently being considered in many states and internationally. Identification of the neuromotor deficits associated with SMA (and other conditions) is often inaccurate or delayed. As new therapies emerge that include gene replacement and gene modifying therapies, clinicians need to consider the expectations of these treatments. Gene replacement therapy is still a mystery to most clinicians. New therapies prompt a reevaluation of current standards of SMA care.

Agenda

  • What do we know and what do we need to know about treatments?
  • Questions from the audience

Faculty

Eugenio Mercuri, MD, PhD (Chair)
Professor of Pediatric Neurology
Catholic University of the Sacred Heart
Rome, Italy

Dr. Eugenio Mercuri is a consultant for AveXis, Biogen, F. Hoffmann-La Roche, and IONIS. He is a principal investigator for Biogen/IONIS and F. Hoffmann-La Roche studies.


Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida, United States

Dr. Richard Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Novartis, and Roche. He receives clinical trial support from AveXis, Biogen, Catabasis, Cytokinetics, Ionis, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.


Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Hartford, Connecticut, United States

Dr. Gyula Acsadi serves as a consultant for AveXis, Biogen, and Serepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Serepta.


Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest

Activity Staff Disclosure

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME information.
  • Complete the CME activity
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis, Inc.

Disclaimer Statement

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME
The France Foundation
Spinal Muscular Atrophy Expert Discussion Conference Series — What Causes SMA? Genetics, Diagnosis, and the Role of SMN

Spinal Muscular Atrophy Expert Discussion Conference Series — What Causes SMA? Genetics, Diagnosis, and the Role of SMN

Start

Conference Series: Part 1 of 3

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: August 21, 2018
Expires: August 20, 2019
15 minutes to complete

Accredited By

Target Audience

Neurologists, pediatric neurologists, neuromuscular specialists, pediatricians, genetic counselors, and other clinicians who see patients with spinal muscular atrophy

Learning Objectives

  • Explain the genetic aspects of SMA, including its recessive nature, carriers, and recommendations for genetic screening
  • Describe criteria for SMA diagnosis

Activity Description

As new therapies emerge for spinal muscular atrophy (SMA) that include gene replacement and gene modifying therapies, clinicians need to consider the expectations for these treatments. Experts, Dr. Eugenio Mercuri, Dr. Richard Finkel, and Dr. Gyula Acsadi, recently discussed these emerging therapies and their implications on the clinical disease state at an international meeting. This activity is a recording of their roundtable discussion with informative slides broken into 3 parts. The first part discusses diagnosis, genetics, and the role of SMN in SMA. Part 2 explains the results of emerging clinical trial data. The final activity is a practical discussion about the implications of these new therapies for this lethal disease. Discussion topics include the durability of new and emerging treatments and changes to the standards of care for patients with SMA. This education is an engaging update on SMA from the leading experts in the field.

Statement of Educational Need

Many clinicians have questions regarding the genetics of spinal muscular atrophy. In addition, carrier screening is not routinely done, despite ACOG recommendations. Routine newborn testing is currently being considered in many states and internationally. Identification of the neuromotor deficits associated with SMA (and other conditions) is often inaccurate or delayed. As new therapies emerge that include gene replacement and gene modifying therapies, clinicians need to consider the expectations of these treatments. Gene replacement therapy is still a mystery to most clinicians. New therapies prompt a reevaluation of current standards of SMA care.

Agenda

  • Introduction to SMA
  • Role of SMN1 and SMN2 genes in SMA
  • Role of SMN protein in development

Faculty

Eugenio Mercuri, MD, PhD (Chair)
Professor of Pediatric Neurology
Catholic University of the Sacred Heart
Rome, Italy

Dr. Eugenio Mercuri is a consultant for AveXis, Biogen, F. Hoffmann-La Roche, and IONIS. He is a principal investigator for Biogen/IONIS and F. Hoffmann-La Roche studies.


Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida, United States

Dr. Richard Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Novartis, and Roche. He receives clinical trial support from AveXis, Biogen, Catabasis, Cytokinetics, Ionis, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.


Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Hartford, Connecticut, United States

Dr. Gyula Acsadi serves as a consultant for AveXis, Biogen, and Serepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Serepta.


Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest

Activity Staff Disclosure

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME information.
  • Complete the CME activity
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis, Inc.

Disclaimer Statement

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME / CNE
AcademicCME
Advancements in the Prevention and Management of Stroke

Advancements in the Prevention and Management of Stroke

Start

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: July 2, 2018
Expires: September 13, 2019
1 hour to complete

Accredited By

Target Audience

Emergency department physicians, neurologists, cardiologists, internists, nurse practitioners, nurses, and other healthcare professionals involved in patient care for prevention and treatment of stroke

Learning Objectives

  • Identify timely assessment strategies to provide the most effective care for patients with stroke
  • Incorporate risk stratification tools into routine clinical practice
  • Explain the latest developments in clinical trials for the treatment and prevention of stroke, including ischemic large hemispheric infarction and stroke-related degeneration
  • Utilize the health care team and shared decision making to achieve improved patient outcomes

Activity Description

This CME/CNE webcast will highlight recent advancements in the prevention and management of stoke. The expert faculty will discuss best practices for assessing risk as well as the modifiable risk factors of stroke. Recent clinical trial data, including that of combination therapy, will be analyzed, as well as strategies for managing the comorbidities that commonly accompany stoke.  Best practices for creating an optimal stroke care team, as outlined by the National Stroke Association, will be reviewed along with models for treatment decision making and implementation. At the conclusion of this discussion-based activity, learners will gain better insight into techniques for optimally treating and managing patients with stroke utilizing a comprehensive, interprofessional approach to care.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with ischemic stroke.

Agenda

  1. Risk Stratification, Prevention and Early Intervention for Patients with Acute Ischemic Stroke
  2. Clinical Trial Update: Data Analysis of Therapeutics for the Prevention and Treatment of Acute Ischemic Stroke
  3. The Importance of Utilizing the Health Care Team and Shared Decision Making to Achieve Improved Patient Outcomes

Faculty

Charles V. Pollack, Jr., MA, MD (Course Chair)
Associate Provost for Innovation in Education
Associate Dean for CME and Strategic Partner Alliances
Department of Emergency Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Director, Jefferson Institute of Emerging Health Professions
Director, The Lambert Center for the Study of Medicinal Cannabis and Hemp
Professor and Senior Advisor for Interdisciplinary Research and Clinical Trials
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania


Rodney D. Bell, MD
Lynne and Harold Honickman Professor of Neurology
Sidney Kimmel Medical School
Thomas Jefferson University
Vice Chairman, Department of Neurology for Hospital Affairs
President of the Medical Staff
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania


John Fanikos, RPh, MBA
Executive Director
Brigham and Women’s Hospital
Clinical Professor
Massachusetts College of Pharmacy
Boston, Massachusetts


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack, Jr., MA, MD
Consultant/Advisor: AstraZeneca; Bristol-Myers Squibb; Boehringer Ingelheim; CSL Behring; Janssen Global Services, LLC; Pfizer Inc.; Portola Pharmaceuticals, Inc.
Grant/Research Support: AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo Company, Limited; Janssen Global Services, LLC; Portola Pharmaceuticals, Inc.

Rodney D. Bell, MD
Nothing to disclose.

John Fanikos, RPh, MBA
Consultant/Advisor: Boehringer Ingelheim; Genentech, Inc.; Portola Pharmaceuticals, Inc.

Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski and Kim Cheramie, MSN, RN-BC hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or Review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  • All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

Statement of Commercial Support

This activity has been supported by independent educational grants from Biogen and the Bristol-Myers Squibb and Pfizer Alliance.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Biogen and the Bristol-Myers Squibb and Pfizer Alliance do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE
Postgraduate Institute for Medicine
Evidence-Based Diagnosis & Management of Multiple Sclerosis

Evidence-Based Diagnosis & Management of Multiple Sclerosis

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit
0.5 ANCC Contact Hour
Released: June 28, 2018
Expires: June 27, 2019
30 minutes to complete

Target Audience

Neurology clinicians, including physicians, nurse practitioners, physician assistants, and neurology nurses

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Recognize and diagnose the spectrum of multiple sclerosis (MS), from clinically isolated syndrome (CIS) to the various forms of MS (relapsing-remitting and progressive forms), using established, updated, clinical imaging and laboratory criteria 
  2. Appropriately use available and emerging disease-modifying therapies (DMTs) for MS based on their efficacy, safety, and tolerability profiles, as well as their approved or anticipated indications for the various forms of MS
  3. Recognize and manage treatment failure, including switching DMTs
  4. Monitor disease and patient outcomes, including patient adherence, according to recommended protocols 
  5. Use shared decision making when prescribing DMTs to improve treatment adherence and patient outcomes

Jointly Provided By


This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Faculty

Patricia K. Coyle, MD, FAAN, FANA
Professor & Vice Chair (Clinical Affairs)
  Department of Neurology
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Patricia K. Coyle, MD, FAAN, FANA, has affiliations with Accordant, Acorda Therapeutics, Bayer, Biogen, Celgene, Genentech/Roche, Genzyme/Sanofi, Novartis, and Serono (Consulting); Actelion, Genentech/Roche, MedDay, NINDS, and Novartis (Contracted Research).

Planners and Managers
The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s). Designated for 0.5 contact hour(s) of pharmacotherapy credit for Advanced Practice Registered Nurses.

How to Receive Credit

Physicians, nurse practitioners, registered nurses, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

Jointly provided by RMEI Medical Education, LLC and Postgraduate Institute for Medicine. This activity is supported by an educational grant from Biogen, Genentech, and Novartis Pharmaceuticals Corporation.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions about the Activity

If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

0.75 CME / CNE
Global Education Group
Multiple sclerosis management: Key clinical take home points from the AAN Annual Meeting

Multiple sclerosis management: Key clinical take home points from the AAN Annual Meeting

Start

Activity Details

Free CME/CNE
0.75 AMA PRA Category 1 Credit
0.75 Contact Hour(s)
Released: June 20, 2018
Expires: June 1, 2019
45 minutes to complete

Accredited By

Global Education Group

Joint Providership Statement

  
This activity is jointly provided by Global Education Group and Strategic Consultants International.

Fee Information

There is no fee for participating in this educational activity.

Target Audience

Neurology physicians, NPs, PAs, and MS Nurses who are interested in the latest insights on the management of patients with multiple sclerosis.

Learning Objectives

At the conclusion of one or more of the proposed activities, participants will be better able to:

  • Describe the recently presented data on the treatment of relapsing remitting and progressive forms of multiple sclerosis (MS)
  • Explain how current management of patients with MS may be adapted to reflect the latest advances.

Activity Description

A series of four faculty video discussions. Each video highlights a different aspect of MS disease management

Statement of Educational Need

Management of MS has advanced dramatically over recent years, with new DMTs becoming available and increasingly, a recognition that ‘NEDA’ is a potential goal of therapy.  As these concepts continue to emerge it is essential that neurologists and MS nurses (and other healthcare providers) caring for patients with MS are fully apprised of recent data.

Importantly, in addition to the actual evidence, clinical interpretation of this information is vital.  To facilitate this, expert insight is necessary to provide a framework for consideration of if/how to amend management approaches in the light of new data and evidence, to improve knowledge and competence, and ultimately, patient care.

Agenda

This activity comprises four individual video discussions. These may be accessed sequentially or as preferred.

Chapter 1. Current and ‘near future’ platform therapies for RRMS
Chapter 2. Highly active injectable DMTs (monoclonal antibodies) in RMS: New data
Chapter 3. Progressive MS
Chapter 4. MS outcomes and predictors of progression

Evaluation and post-test

Faculty

Patricia Coyle, MD
Vice Chair, Department of Neurology, Director, MS Comprehensive Care Center,
Stony Brook University Hospital, East Setauket, New York


Stephen Krieger, MD
Associate Professor of Neurology, Corinne Goldsmith Dickinson Center for MS
Director, Neurology Residency Program, Icahn School of Medicine at Mount Sinai, New York


Gabriel Pardo, MD
Director, OMRF Multiple Sclerosis Center of Excellence
Associate Member, Arthritis & Clinical Immunology Research Program
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma


Jerry Wolinsky, MD
Emeritus Professor in Neurology
McGovern Medical School, part of UTHealth
The University of Texas Health Science Center at Houston, Houston, Texas


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Patricia Coyle, MD
Consultant/Independent Contractor:
Accordant, Acorda, Bayer, Biogen, Celgene, EMD Serono, Genentech/Roche, Novartis, Sanofi-Genzyme
Grant/Research Support:
Actelion, Genentech/Roche, MedDay, Novartis

Stephen Krieger, MD
Consultant/Independent Contractor:
Acorda, Biogen, Celgene, EMD Serono, Genentech, Genzyme, Mallincrodt, Novartis, Teva, TG therapeutic

Gabriel Pardo, MD
Consultant/Independent Contractor:
Biogen, EMD Serono, Genentech, Genzyme, Novartis, Teva

Jerry Wolinsky, MD
Consultant/Independent Contractor:
AbbVie, Actelion, Biogen, Celgene, Clene Nanomedicine, EMD Serono, Forward Pharma A/S, GeNeuro, Genentech/Roche, McDonnel Boehnen Hulbert & Berghoff, MedDay Pharmaceuticals, Novartis Pharmaceuticals, Otsuka, PTC Therapeutics, Sanofi-Genzyme
Honorarium:
AcademicCME, ACTRIMS, Alkermes, CMSC, ECTRIMS, France Foundation, Masters MS (Annenberg Center for Health Sciences at Eisenhower), PlatformQ Health Education, PRIME, Strategic Consultants International, Society for Clinical Trials, WebMD
Royalty:
For out licensed monoclonal antibodies through UTHealth to Millipore (Chemicon International) Corporation

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Lindsay Borvasnky
Nothing to disclose

Ashley Marostica
Nothing to disclose

Liddy Knight
Nothing to disclose

Ian Morgan
Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Strategic Consultants International (SCI). Global is accredited by the ACCME to provide continuing medical education for physicians.

Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation .

Designation of Credit

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation
This educational activity for 0.75 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit for this activity, the participant must review the materials, complete the post-activity test with a pass mark of 65% or greater and complete the evaluation and credit request.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Strategic Consultants International (SCI) do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE
AcademicCME
Clinical Trial Update: Therapeutic Strategies to Delay Disease Progression

Clinical Trial Update: Therapeutic Strategies to Delay Disease Progression

Start

Accredited By

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credits
0.5 CNE Contact Hours
Released: December 7, 2017
Expires: April 5, 2019
30 Minutes to complete

Target Audience

Neurologists, internists, nurse practitioners, and other healthcare professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

  1. Analyze clinical trial data of emerging therapeutics to delay progression in the treatment of AD
  2. Implement shared decision making with the multidisciplinary team and patients/caregivers to develop individualized treatment plans and referral to clinical studies to advance treatment and improve the quality of life for patients with AD

Activity Description

In this module of a Four-Part Expert Interview Series, Dr. Marc E. Agronin, along with Dr. Richard S. Isaacson, course chair, will evaluate available therapeutic options for Alzheimer’s disease (AD) patient. The faculty will highlight the evolution of failed and existing therapies in AD, and their impact on current clinical care, emphasizing strategies for delaying disease progression in the modern day. Emerging therapies for the treatment and management of Alzheimer’s disease will also be assessed. Through completing this educational activity, learners will be better acquainted with emerging and emerged clinical trial data as it relates to AD care.

Statement of Educational Need

Health care team members need to be up-to-date on the most current strategies to delay disease progression in Alzheimer’s patients.

Agenda

Clinical Trial Update: Therapeutic Strategies to Delay Disease Progression

Faculty

Program Chair:
Richard S. Isaacson, MD

Associate Professor of Neurology
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York


Program Faculty:
Marc E. Agronin, MD

Vice President, Behavioral Health and Clinical Research
Miami Jewish Health
Affiliate Associate Professor of Psychiatry and Neurology
University of Miami Miller School of Medicine
Miami, Florida


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.


Faculty
Relationship Identified With:
Richard S. Isaacson, MD
Consultant/Advisor: Eli Lilly and Company; Neurotrack; 23 and Me
Marc E. Agronin, MD
Consultant/Advisor: Eli Lilly and Company
Speaker's Bureau: Allergan

Non-faculty

Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski, Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

Designation of Credit

AcademicCME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 0.5 CNE contact hours.

Instructions for Receiving Credit

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

Statement of Commercial Support

This activity has been supported by an independent educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE
AcademicCME
The Role of Beta-Amyloid and Tau: CSF Protein Levels and PET Imaging

The Role of Beta-Amyloid and Tau: CSF Protein Levels and PET Imaging

Start

Accredited By

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credits
0.5 CNE Contact Hours
Released: December 7, 2017
Expires: TBD
30 Minutes to complete

Target Audience

Neurologists, internists, nurse practitioners, and other healthcare professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

  1. Discuss recent developments in the diagnosis of AD such as the role of beta-amyloid and tau biomarkers
  2. Implement shared decision making with the patient and caregiver to develop individualized approach to diagnosis and treatment to improve the quality of life for patients with AD

Activity Description

In this module of a Four-Part Expert Interview Series, Dr. Barry W. Rovner, along with Dr. Richard S. Isaacson, course chair, will provide learners with an update regarding beta-amyloid and tau biomarkers and their role in Alzheimer’s disease (AD) pathology and progression. Recent guidelines and trial data relating to beta-amyloid and tau will be reviewed, and clinical relevance debated. Drs. Rovner and Isaacson will also discuss the diagnostic criteria for Alzheimer’s disease and intervention techniques for the various stages of disease. Upon completion of this educational activity, learners will be better equipped with best practices for managing beta amyloid and tau levels in practice to provide optimal care for patients with AD.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of AD patients, including beta-amyloid and tau biomarkers.

Agenda

The Role of Beta-Amyloid and Tau: CSF Protein Levels and PET Imaging

Faculty

Program Chair:
Richard S. Isaacson, MD

Associate Professor of Neurology
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York


Program Faculty:
Barry W. Rovner, MD

Professor, Departments of Neurology, Psychiatry, and Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
Jefferson Hospital for Neuroscience
Philadelphia, Pennsylvania


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.


Faculty
Relationship Identified With:
Richard S. Isaacson, MD
Consultant/Advisor: Eli Lilly and Company; Neurotrack; 23 and Me
Barry W. Rovner, MD
Nothing to disclose.

Non-faculty

Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski, Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

Designation of Credit

AcademicCME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 0.5 CNE contact hours.

Instructions for Receiving Credit

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

Statement of Commercial Support

This activity has been supported by an independent educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE
AcademicCME
Early Diagnosis and Disease Monitoring: Pathology and Biomarkers

Early Diagnosis and Disease Monitoring: Pathology and Biomarkers

Start

Accredited By

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credits
0.5 CNE Contact Hours
Released: December 7, 2017
Expires: April 5, 2019
30 Minutes to complete

Target Audience

Neurologists, internists, nurse practitioners, and other healthcare professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

  1. Review the pathology of Alzheimer’s disease, including disease monitoring and specific biomarkers for early diagnosis
  2. Identify the assessment and testing strategies for early diagnosis, monitoring, and personalized treatment of AD

Activity Description

In this module of a Four-Part Expert Interview Series, Max Lugavere, along with Dr. Richard S. Isaacson, course chair, will explore non-pharmacological approaches to managing patients with Alzheimer’s disease (AD). Multi-modal intervention factors, including nutrition exercise, sleep hygiene and continued education, among others, will be reviewed, and best practices relayed. The faculty will also highlight recent clinical trial data regarding non-pharmacological methods of AD patient care. Clinical relevance of said data, both now and in the pipeline, will be deliberated. Following this educational activity, learners will have a better grasp of non-pharmacological intervention techniques as well as their potential impact in current and forthcoming AD patient care.

Statement of Educational Need

Health care team members need to understand the pathology of Alzheimer’s disease in order to treat it most effectively, including the biomarkers for early diagnosis.

Agenda

Early Diagnosis and Disease Monitoring: Pathology and Biomarkers

Faculty

Program Chair:
Richard S. Isaacson, MD

Associate Professor of Neurology
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York


Program Faculty:
James E. Galvin, MD, MPH

Professor and Associate Dean for Clinical Research
Director, Comprehensive Center for Brain Health
Charles E. Schmidt College of Medicine
Florida Atlantic University
Boca Raton, Florida


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.


Faculty
Relationship Identified With:
Richard S. Isaacson, MD
Consultant/Advisor: Eli Lilly and Company; Neurotrack; 23 and Me
James E. Galvin, MD, MPH
Nothing to disclose.

Non-faculty

Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski, Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

Designation of Credit

AcademicCME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 0.5 CNE contact hours.

Instructions for Receiving Credit

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

Statement of Commercial Support

This activity has been supported by an independent educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Pages